Okamoto Y, Hirota S, Soejima T, Maeda H, Takada Y, Hasegawa K, Hishikawa Y
Department of Radiology, Hyogo Medical Center for Adults.
Nihon Igaku Hoshasen Gakkai Zasshi. 1997 Dec;57(14):936-41.
One hundred three patients with adenocarcinoma of the uterine cervix treated with radiotherapy between 1975 and 1992 were evaluated. The results for 24 patients treated with radiotherapy alone were as follows: The overall 5-year survival rates for Stages I + II (N = 12) and III + IV (N = 12) were 52% and 16%, respectively, lower than those for squamous cell carcinoma (stage I: 89%, II: 54%, III: 44%, IV: 19%). The overall response rate was 79.1%, and the recurrence rate was 54.2% (local recurrence: 29.2%, distant metastasis: 33.3%). In Stage I + II patients with an intracavitary irradiation dose of 40 Gy (LDR) or more, there was no local recurrence. In stage III + IV patients, local recurrence was recognized in spite of the high dosage of intracavitary irradiation. The results for 79 patients treated with combined irradiation and operation were as follows: The overall 5-year survival rates for Stages I, II, III and IV were 76%, 60%, 57%, and 0%, respectively. The incidence of lymph node metastasis was 30.4%, and for Stages I, II, III and IV was 26.7%, 34.6%, 28.6%, and 100%, respectively. This showed that adenocarcinoma had a higher incidence of lymph node metastasis after the early stage. The recurrence rate for patients with lymph node metastasis was 75.0%, significantly higher than 25.4% for patients without lymph node metastasis (p < 0.001). To improve prognosis, 40 Gy or more of intracavitary irradiation dose (LDR) and systemic chemotherapy to prevent distant metastasis are recommended for stage I and II cases. For stage III and IV cases, it was thought to be difficult to control local disease with radiation alone. Additional treatment should be used for these cases, i.e. intraarterial infusion, chemotherapy, hyperthermia and so on.
对1975年至1992年间接受放疗的103例子宫颈腺癌患者进行了评估。24例单纯接受放疗患者的结果如下:I + II期(N = 12)和III + IV期(N = 12)的总体5年生存率分别为52%和16%,低于鳞状细胞癌(I期:89%,II期:54%,III期:44%,IV期:19%)。总体缓解率为79.1%,复发率为54.2%(局部复发:29.2%,远处转移:33.3%)。在腔内照射剂量为40 Gy(低剂量率)或更高的I + II期患者中,无局部复发。在III + IV期患者中,尽管腔内照射剂量很高,但仍出现了局部复发。79例接受联合放疗和手术患者的结果如下:I、II、III和IV期的总体5年生存率分别为76%、60%、57%和0%。淋巴结转移发生率为30.4%,I、II、III和IV期分别为26.7%、34.6%、28.6%和100%。这表明腺癌在早期之后淋巴结转移发生率较高。有淋巴结转移患者的复发率为75.0%,显著高于无淋巴结转移患者的25.4%(p < 0.001)。为改善预后,建议I期和II期病例采用40 Gy或更高的腔内照射剂量(低剂量率)以及全身化疗以预防远处转移。对于III期和IV期病例,认为仅用放疗难以控制局部疾病。这些病例应采用额外的治疗方法,即动脉内灌注、化疗、热疗等。